Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Mooi nieuws . July 7, 2017 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that its abstract covering the complete data set from its Phase Ib study of ARGX-111 in patients with advanced cancers over-expressing the MET protein was selected as part of the Best of ASCO program at the 3rd Singapore Society of Oncology Annual Scientific Meeting in Singapore. "The differentiated design of ARGX-111 to enhance killing of advanced tumor cells offers a really exciting approach to treating patients with MET-driven cancers," commented Nicolas Leupin, Chief Medical Officer of argenx. "We are pleased to see preliminary anti-tumor activity and a consistently favorable safety profile, which was the goal of this expansion study. These data offer a compelling path forward to further examine in a Phase 2 study the activity of ARGX-111, which we are looking to strategically partner." The new data from the Phase Ib study continue to show evidence of anti-tumor activity with ARGX-111 at all dose levels and across different indications. Partial response and stable disease were observed, respectively, in one and nine of 24 heavily pretreated patients with MET-positive malignancies, both MET-gene-amplified and with MET overexpression. Treatment-emerging adverse events were reported for all patients, but none of the grade 5 toxicities were related to ARGX-111. The poster presented at Best of ASCO can be accessed from the "Downloads" section of the argenx website. About ARGX-111 ARGX-111 was developed for the treatment of patients with certain solid tumors that overexpress c-Met, a receptor associated with tumor growth and metastasis, or tumors that are mesenchymal-epithelial transition factor, or MET, amplified. ARGX-111 employs the SIMPLE AntibodyTM, NHance® and POTELLIGENT® technologies to drive tissue penetration in the body and to increase its ability to enhance ADCC. ARGX-111 binds to c-Met with high affinity and does not cause dimerization of the c-Met receptor, which differentiates it from other, earlier attempts to direct antibodies against c-Met. Dimerization is a process which can result in receptor activation, undermining the intended therapeutic effect of antibodies blocking hepatocyte growth factor, or HGF, binding to c-Met. By blocking both HGF-dependent and independent c-Met activation, ARGX-111 is able to block c-Met receptor activation which could trigger survival, proliferation and metastasis of tumor cells. In order to further examine the activity of the product candidate in a Phase 2 study, argenx is actively looking for an appropriate collaboration partner.
Ze willen dus zoeken naar een partner . Moet lukken . Overigens koers USA gisteren nog voor het mooie nieuws van vandaag : 20,40
argenx SE – American Depositary Shares (NASDAQ:ARGX) Research Coverage Started at JMP Securities July 6th, 2017 - By Doug Wharley - 0 comments argenx SE - American Depositary Shares logoJMP Securities initiated coverage on shares of argenx SE – American Depositary Shares (NASDAQ:ARGX) in a report released on Monday, June 12th, MarketBeat.com reports. The brokerage issued an outperform rating and a $33.00 price objective on the stock. Separately, Cowen and Company began coverage on argenx SE – American Depositary Shares in a research report on Monday, June 12th. They set an outperform rating on the stock. argenx SE – American Depositary Shares (NASDAQ:ARGX) traded up 0.44% during midday trading on Monday, reaching $20.40. 59,300 shares of the company’s stock traded hands. argenx SE – American Depositary Shares has a one year low of $17.33 and a one year high of $25.00. The stock’s market cap is $548.17 million. The stock’s 50 day moving average price is $20.80 and its 200-day moving average price is $20.80.
USA slot 20,33 dollar = 17,85 met een hoger volume dan in Europa . Staan wij hier op een schamele 17,41 .
Idem slot gisteren USA 20,35 US = huidig Euro 17,81 En dan staan we hier op 17,27 te klooien . Onbegrijpelijk . Zeker omdat de omzetten in de USA veel hoger zijn . Is dit Hollandse zuinigheid
Zozo . USA slot 20,63 $ = 17,99 euro
Zit er een nieuwe partner aan te komen ? Gisteren in de USA zo maar 21,42 slot = 18,39 euro About ARGX-111 ARGX-111 was developed for the treatment of patients with certain solid tumors that overexpress c-Met, a receptor associated with tumor growth and metastasis, or tumors that are mesenchymal-epithelial transition factor, or MET, amplified. ARGX-111 employs the SIMPLE AntibodyTM, NHance® and POTELLIGENT® technologies to drive tissue penetration in the body and to increase its ability to enhance ADCC. ARGX-111 binds to c-Met with high affinity and does not cause dimerization of the c-Met receptor, which differentiates it from other, earlier attempts to direct antibodies against c-Met. Dimerization is a process which can result in receptor activation, undermining the intended therapeutic effect of antibodies blocking hepatocyte growth factor, or HGF, binding to c-Met. By blocking both HGF-dependent and independent c-Met activation, ARGX-111 is able to block c-Met receptor activation which could trigger survival, proliferation and metastasis of tumor cells. In order to further examine the activity of the product candidate in a Phase 2 study, argenx is actively looking for an appropriate collaboration partner. ,, In order to further examine the activity of the product candidate in a Phase 2 study, argenx is actively looking for an appropriate collaboration partner. ,,
argenx to present at Wedbush PacGrow Healthcare Conference August 08, 2017 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that Chief Executive Officer, Tim Van Hauwermeiren, will present a corporate update at the Wedbush PacGrow Healthcare Conference in New York on Tuesday, August 15, 2017 at 1:20 p.m. EDT. The presentation will be webcast live and may be accessed on the argenx website at www.argenx.com or by clicking here. A replay of the webcast will be available for 90 days following the presentation. About argenx argenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. We are focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. Our ability to execute on this focus is enabled by our suite of differentiated technologies. Our SIMPLE Antibody™ Platform, based on the powerful llama immune system, allows us to exploit novel and complex targets, and our three antibody engineering technologies are designed to enable us to expand the therapeutic index of our product candidates. www.argenx.com For further information, please contact: Joke Comijn, Corporate Communications Manager +32 (0)477 77 29 44 +32 (0)9 310 34 19info@argenx.com
Morgen (di 15.08) een research update dus?
Lummel37 schreef op 14 augustus 2017 11:29 :
Morgen (di 15.08) een research update dus?
het congres is 2 dagen . Vooral verder op de kaart zetten / bekendheid etc Ik ga er van uit dat er snel nieuws kan komen ivm nieuwe partner mogelijkheid
? Het zal wel aan mij liggen . USA 21,97 = euro 18,77 Hier gewoon 17,19
Mooie ontwikkelingen Published: 07:00 CEST 24-08-2017 /GlobeNewswire /Source: argenx SE / : ARGX /ISIN: NL0010832176 argenx reports second quarter business update and half-year 2017 financial results Management to host conference call today at 3 p.m. CEST / 9 a.m. EDT August 24, 2017 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced its second quarter business update and half-year financial results for 2017. The half-year results will be discussed during a conference call and webcast presentation today at 3 p.m. CEST/ 9 a.m. EDT. To participate in the conference call, please select your phone number below, and use the confirmation code 3427020. The webcast may be accessed on the homepage of the argenx website at www.argenx.com or by clicking here. "The first half of 2017 has been a period of momentous growth for argenx. We completed our U.S. public offering on Nasdaq, which not only broadened our U.S. shareholder base, but also provided us with additional capital to push forward the development of our two lead drug candidates ARGX-113 and ARGX-110. ARGX-113 is progressing in both MG and ITP studies. ARGX-110 is continuing to show encouraging signs of biological activity and a promising safety profile in CTCL patients and is being tested in a combination trial in newly diagnosed AML patients. We expect to have top-line data from the Phase 2 studies in 2018," commented Tim Van Hauwermeiren, CEO of argenx. "We also furthered our commitment to our antibody pipeline, which we continue to grow through our strategic collaborations. We announced two new partnerships this year with Staten Biotech and Broteio in very exciting therapeutic areas and made progress with our ongoing collaborations with AbbVie and Leo resulting in two milestone payments in the second quarter. Through both our wholly-owned and partnered programs, we are driving our mission forward to develop differentiated antibody candidates for patients in need." SECOND QUARTER 2017 AND RECENT BUSINESS HIGHLIGHTS Products in clinical development: ARGX-113 Reached 50% enrollment in Phase 2 clinical trial of ARGX-113 in myasthenia gravis (MG). The double-blind, placebo-controlled Phase 2 study is enrolling up to 24 MG patients with confirmed generalized muscle weakness. ARGX-110 Launched Phase 2 study of ARGX-110 as a monotherapy in relapsed/refractory cutaneous T-cell lymphoma (CTCL) patients. The goal of the study is to further evaluate the intrinsic activity of the drug in CTCL patients and to broaden the safety and efficacy database. Presented updated data from Phase 1b expansion study of ARGX-110 in patients with CTCL at the International Conference of Malignant Lymphoma (ICML). Data continue to show evidence of clinical and/or biological anti-tumor activity across different CTCL subtypes and different disease stages. ARGX-111 Met safety endpoints in the Phase 1 clinical trial. Complete data set presented from ARGX-111 Phase 1b study in patients with advanced cancers over-expressing the MET protein at Best of ASCO Asia 2017 (Singapore). Collaborations: Received first of two preclinical milestone payments from AbbVie under our collaboration for ARGX-115, triggering a $10 million payment from AbbVie. Received second preclinical milestone payments in collaboration with LEO Pharma for ARGX-112. argenx is responsible for conducting ARGX-112 research and development activities up to a first filing by LEO Pharma for clinical trial application (CTA) approval. Announced publication of new preclinical data in 'Nature Medicine' on ARGX-116 inhibiting ApoC3, a metabolic target correlated with blood lipid levels, that provide further rationale for the therapeutic potential of ARGX-116 for the treatment of dyslipidemia. Corporate: Continued execution of intellectual property strategy with multiple grants and notices of allowance for SIMPLE AntibodyTM platform (U.S. and EU), ARGX-110 (U.S., EU, and Japan) and ARGX-111 (Japan and EU). argenx now has 128 patents granted and 68 pending patent applications. Increased headcount to 67 persons in support of the expansion of the business. FINANCIAL HIGHLIGHTS (as of June 30, 2017) (compared to financial highlights as of June 30, 2016) Raised approximately €102 million ($115 million) of gross proceeds (before underwriter discounts and commissions and offering expenses) with Nasdaq initial public offering (IPO) in the United States of 6,744,750 American Depositary Shares (ADSs), at a price to the public of $17.00 per ADS. This includes the full exercise of the underwriters' option to purchase additional ADSs. Operating income of €23.9 million (June 30, 2016: €7.0 million). Total comprehensive loss of €8.2 million (June 30, 2016: €7.4 million). Cash position of €173.4 million (cash, cash-equivalents and current financial assets) allowing argenx to pursue development of its pipeline as planned. UPCOMING MILESTONES ARGX-113 Topline data from Phase 2 study in MG expected in 1Q 2018 and topline data from Phase 2 study in ITP expected in 2H 2018. Initiation of Phase 1 clinical trial of subcutaneous dosing in healthy volunteers expected in 2H 2017. ARGX-110 Interim data from Phase 1/2 study in AML and Phase 2 study in CTCL each expected by the end of 2017 (workshop in conjunction with the ASH Annual Meeting), and topline data from Phase 2 study in CTCL expected by the end of 2018.argen-x.com/en-GB/news-internal/argen...
Onopvallend en onder de radar dendert Argen-X door . Fly heeft al meermaals gezegd dat er veels te weinig aandacht voor is . Nu zie ik hem zelfs niet meer !? Ik zit er al in vanaf de 10 euro( dankzij Fly en onderzoek) en blijf hier LT ( net als Ablynx ) inzitten . Tenzij er iets negatiefs zou opduiken uiteraard . Voorlopig gaat dit bedrijf een steeds grotere opmars maken . Nog niet ontdekt door de grote kudde . Dit gaat nog wel gebeuren .argen-x.com/en-GB/content/argenx-in-s... Published: 07:00 CEST 20-09-2017 /GlobeNewswire /Source: argenx SE / : ARGX /ISIN: NL0010832176 argenx reaches 50% enrollment in Phase 2 clinical trial of ARGX-113 in immune thrombocytopenia Top-line data from the study expected in second half of 2018 - September 20, 2017 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that it has recruited 50% of the immune thrombocytopenia (ITP) patients in the Phase 2 proof-of-concept study of ARGX-113. "We are pleased to have reached the 50% recruitment milestone in this study, which is enrolling on schedule," commented Nicolas Leupin, Chief Medical Officer of argenx. "We remain on track, and look forward to presenting top-line data from the ARGX-113 clinical trial in ITP in the second half of 2018, which will be our second indication with Phase 2 top-line data from ARGX-113." The double-blind, placebo controlled Phase II study will enroll up to 36 ITP patients with platelet levels lower than 30 million per milliliter. ARGX-113 will be dosed on top of current standard of care, including corticosteroids and/or immunomodulatory agents and/or TPO-R agonists. The primary endpoints of the trial are safety and tolerability, and secondary endpoints are effect on platelet count and use of rescue treatment, and an assessment of pharmacokinetics (PK) and pharmacodynamic (PD) markers. The ITP clinical trial was initiated in March 2017. ARGX-113 is also being studied in a Phase 2 proof-of-concept study for the treatment of myasthenia gravis (MG), which was initiated in January 2017. About ARGX-113 ARGX-113 is an investigational therapy for treatment of IgG-mediated autoimmune diseases. ARGX-113 is the Fc-portion of an antibody that has been modified by the argenx proprietary ABDEG(TM) technology to increase its affinity for FcRn beyond that of normal IgG antibodies. As a result, ARGX-113 blocks antibody recycling and leads to fast depletion of the autoimmune disease-causing IgG autoantibodies. The development work on ARGX-113 is done in close collaboration with Prof. E. Sally Ward (University of Texas Southwestern Medical and Texas A&M University Health Science Center, a part of Texas A&M University (TAMHSC)). About argenx argenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. We are focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. Our ability to execute on this focus is enabled by our suite of differentiated technologies. Our SIMPLE Antibody(TM) Platform, based on the powerful llama immune system, allows us to exploit novel and complex targets, and our three antibody engineering technologies are designed to enable us to expand the therapeutic index of our product candidates. www.argenx.com For further information, please contact: Joke Comijn, Corporate Communications Manager +32 (0)477 77 29 44 +32 (0)9 310 34 19info@arGEN-X.com Beth DelGiacco (US IR) Stern Investor Relations +1 212 362 1200beth@sternir.com
Op 30 september organiseert VFB 'De dag van de tips' in Flanders Expo, Gent. Een van de gastsprekers zal Tim Van Hauwermeiren van Argenx zijn. Is sowieso een goeie zaak voor wat meer ruchtbaarheid rond het aandeel, lijkt me.www.vfb.be/Vfb/
ZEER GOED NIEUWS argenx announces orphan drug designation for ARGX-113 for the treatment of myasthenia gravis Non-regulated information September 25, 2017 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA) has granted orphan status for the use of ARGX-113 for the treatment of myasthenia gravis. MG is an autoimmune disorder associated with muscle weakness that is triggered by IgG auto-antibodies. These antibodies attack critical signalling proteins at the junction between nerve and muscle cells, thereby impairing their communications signals. There are limited effective and sustainable treatments for MG. ARGX-113 has the potential to eliminate patient symptoms while minimizing common side effects seen with current treatments by reducing the pathogenic IgG levels. About orphan drug designation Orphan drug status is granted by FDA to a drug or biological product to treat a rare disease or condition upon request of a sponsor. Orphan drug designation qualifies for various development incentives, including tax credits for qualified clinical testing, a waiver from FDA's application User Free for marketing application, and a 7-year period of marketing exclusivity in the US. The granting of an orphan designation request does not alter the standard regulatory requirements and process for obtaining marketing approval. Safety and effectiveness of a drug must be established through adequate and well-controlled studies. About ARGX-113 ARGX-113 is an investigational therapy for treatment of IgG-mediated autoimmune diseases. ARGX-113 is the Fc-portion of an antibody that has been modified by the argenx proprietary ABDEG(TM) technology to increase its affinity for FcRn beyond that of normal IgG antibodies. As a result, ARGX-113 blocks antibody recycling and leads to fast depletion of the autoimmune disease-causing IgG autoantibodies. The development work on ARGX-113 is done in close collaboration with Prof. E. Sally Ward (University of Texas Southwestern Medical and Texas A&M University Health Science Center, a part of Texas A&M University (TAMHSC)).
Inderdaad mooi nieuws, maar extreem weinig reactie in de koers. Wel een veel grotere handel vandaag. Voor Galapagos heb ik voor ieder medicijn een apart topic geopend met daarin alle info die beschikbaar is. Omdat het hier nog vrij rustig is, kan ik die info wel in dit topic plakken denk ik. Hieronder alles wat ik zo snel even kon vinden. Vul gerust aan of verbeter waar nodig:Medicijn: ARGX-109 (Gerilimzumab)Ziekte: Rheumatoid Arthritis (RA)Huidige onderzoeksfase: Fase 1 afgerond? Resultaten al bekend?Opmerking: Partnered met Bird Rock?Medicijn: ARGX-110 (Cusatuzumab)Ziekte 1: Cutaneous T-Cell Lymphoma (CTCL)Ziekte 2: Acute Myeloid LeukemiaHuidige onderzoeksfase: Fase 2 onderzoek in T-Cell Lymphoma met verwachte resultaten in H2 2018. Interim update verwacht tegen het einde van 2017 voor CTCL, en voor fase 1 dose-escalation in AML en MDS (welke indicatie is dit?)Medicijn: ARGX-111Ziekte: Solid Tumors / Blood CancerHuidige onderzoeksfase: Met safety endpoints in the Phase 1 clinical trial. Complete data set presented from ARGX-111 Phase 1b study in patients with advanced cancers over-expressing the MET protein at Best of ASCO Asia 2017 (Singapore). Opmerking: Op zoek naar een partner om fase 2 mee te doen.Medicijn: ARGX-112Ziekte: Skin inflammationHuidige onderzoeksfase: Preklinisch?Opmerking: Partnered met LEO?Medicijn: ARGX-113 (Efgartigimod)Ziekte 1: Myasthenia Gravis (MG)*Ziekte 2: Immune Thrombocytopenia (ITP)Ziekte 3: Chronic Autoimmune DiseasesHuidige onderzoeksfase: Fase 2 onderzoek in MG en ITP met verwachte resultaten in H2 2018. Start van fase 1 in CAD in H2 2017Opmerking: Weesgeneesmiddelstatus sinds 25 september 2017 voor MG* MG is an autoimmune disorder associated with muscle weakness that is triggered by IgG auto-antibodies. These antibodies attack critical signalling proteins at the junction between nerve and muscle cells, thereby impairing their communications signals. There are limited effective and sustainable treatments for MG. ARGX-113 has the potential to eliminate patient symptoms while minimizing common side effects seen with current treatments by reducing the pathogenic IgG levels. Medicijn: ARGX-115Ziekte: Cancer ImmunotherapyHuidige onderzoeksfase: PreklinischOpmerking: Partnered met AbbVie sinds 20 april 2016Medicijn: ARGX-116Ziekte: DyslipidemiaHuidige onderzoeksfase: PreklinischOpmerking: Partnered met Staten Biotechnology
@Pokerface: Thnx voor je overzichtje.
En wederom een mooi nieuw bericht . En velen zitten op de biotechaandelen met een kleine pipeline en vergeten de snel expanderende Argen-X Published: 07:00 CEST 26-09-2017 /GlobeNewswire /Source: argenx SE / : ARGX /ISIN: NL0010832176 argenx launches Phase II proof-of-concept clinical trial of ARGX-113 for the treatment of pemphigus vulgaris Interim data expected in H2 2018 September 26, 2017 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced the initiation of a Phase II proof-of-concept clinical trial of ARGX-113 in pemphigus vulgaris (PV) patients. "PV is a chronic, severe and potentially life-threatening orphan auto-immune disease of the skin for which limited treatment options exist. Disease severity is directly correlated to pathogenic antibodies of the immunoglobulin G (IgG) type targeting desmoglein-1 and -3 in the skin, leading to painful blister formation and skin damage," commented Nicolas Leupin, Chief Medical Officer of argenx. "Current treatment options are limited to high-dose steroids and chronic immunosuppression. We are thrilled about the therapeutic potential of ARGX-113 in PV, based on its mode of action of clearing IgGs. PV represents a clean and rapid proof-of-concept indication and, we believe, is therefore our ideal beachhead into the field of severe auto-immune blistering diseases of the skin." The open-label, non-controlled Phase II clinical trial will enroll up to 12 patients with mild to moderate PV who are either newly diagnosed or relapsing. The primary endpoints of the trial are safety and tolerability, and secondary endpoints include efficacy and an assessment of pharmacokinetics (PK) and pharmacodynamic (PD) markers. The study design will be presented in more detail during a PV Key Opinion Leader event which will take place in New York on November 10, 2017. ARGX-113 is currently being tested in two additional Phase II clinical trials in myasthenia gravis (MG) and immune thrombocytopenia (ITP). Topline date for MG and ITP are expected in the first quarter and second half of 2018, respectively. In a Phase I clinical trial, ARGX-113 was well-tolerated across multiple doses and dosing regimens with promising pharmacodynamic effects relating to speed, depth and duration of IgG reduction. About ARGX-113 ARGX-113 is an investigational therapy for treatment of IgG-mediated autoimmune diseases. ARGX-113 is the Fc-portion of an antibody that has been modified by the argenx proprietary ABDEG(TM) technology to increase its affinity for FcRn beyond that of normal IgG antibodies. As a result, ARGX-113 blocks antibody recycling and leads to fast depletion of the autoimmune disease-causing IgG autoantibodies. The development work on ARGX-113 is done in close collaboration with Prof. E. Sally Ward (University of Texas Southwestern Medical and Texas A&M University Health Science Center, a part of Texas A&M University (TAMHSC)). About argenx argenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. We are focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. Our ability to execute on this focus is enabled by our suite of differentiated technologies. Our SIMPLE Antibody(TM) Platform, based on the powerful llama immune system, allows us to exploit novel and complex targets, and our three antibody engineering technologies are designed to enable us to expand the therapeutic index of our product candidates. www.argenx.com For further information, please contact: Joke Comijn, Corporate Communications Manager +32 (0)477 77 29 44 +32 (0)9 310 34 19info@argenx.com
Beste Pokerface . Bedankt voor je overzicht Er is echter op de website ook een perfect overzicht :argen-x.com/en-GB/content/overview/13/ argen-x.com/handlers/download.ashx?fi... Na zoveel nieuwe persberichten wordt het wel tijd voor een nieuwe corporate presentation
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Premium
Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!
Word abonnee